Bull
$150.52
情境價格
$261.750
-0.628 (-0.24%)收盤時
IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Commercial Solutions and Research & Development Solutions. Its commercial solutions provide mission critical information, advanced analytics, technology solutions, health care provider services (including contract sales), and patient engagement services to the Company’s life science clients. Its research & development solutions primarily serve biopharmaceutical customers, provide outsourced clinical research, clinical trial and real-world research related services. The Company offers clinical products, commercial products, compliance, safety, reg products, real world products, and others. Its clinical products include planning suite, grant plan, site suite, clinical trial payments, investigator site portal, one home for sites, patient engagement suite and others.
IQVIA Holdings Inc is a good buy right now due to its current price of $261.75, which is below the analyst price target of $288 from TD Cowen, suggesting a potential upside of 9.93%. Additionally, the company's forward P/E ratio of 20.28 indicates reasonable valuation compared to its growth prospects. However, the main risk is the insider selling activity, with a 1004.81% increase in insider selling over the last month, which may signal caution among executives.
TD Cowen
$288
2026-07-29
TD Cowen
2026-07-29
目標價
$288
BofA
$280
2026-07-29
BofA
2026-07-29
目標價
$280
RBC Capital
$247
2026-07-29
RBC Capital
2026-07-29
目標價
$247
BMO Capital
$270
2026-07-29
BMO Capital
2026-07-29
目標價
$270
JPMorgan
$285
2026-07-29
JPMorgan
2026-07-29
目標價
$285
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

IQVIA Recognized with Multiple Industry Awards for AI Innovations

IQVIA's AI Tool Wins 2026 Breakthrough Award

IQVIA Ranked No. 1 in Everest Group's 2026 Pharmaceutical Technology Providers

IQVIA Executive Sells 558 Shares at $245.21 Each

IQVIA Executive Sells 5,000 Shares, Reducing Holdings by 19%
IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Commercial Solutions and Research & Development Solutions. Its commercial solutions provide mission critical information, advanced analytics, technology solutions, health care provider services (including contract sales), and patient engagement services to the Company’s life science clients. Its research & development solutions primarily serve biopharmaceutical customers, provide outsourced clinical research, clinical trial and real-world research related services. The Company offers clinical products, commercial products, compliance, safety, reg products, real world products, and others. Its clinical products include planning suite, grant plan, site suite, clinical trial payments, investigator site portal, one home for sites, patient engagement suite and others. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).
IQVIA Holdings Inc is a good buy right now due to its current price of $261.75, which is below the analyst price target of $288 from TD Cowen, suggesting a potential upside of 9.93%. Additionally, the company's forward P/E ratio of 20.28 indicates reasonable valuation compared to its growth prospects. However, the main risk is the insider selling activity, with a 1004.81% increase in insider selling over the last month, which may signal caution among executives.
17 analysts cover IQV: 9 rate it Buy, 8 Hold and 0 Sell. The average price target is 258.31.
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。